Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Rentel is currently Executive Director, Analytical Development and Quality Control at Ionis Pharmaceuticals, Inc., Carlsbad, California. Prior to joining Ionis in 2001 he worked in Quality Control and Special Analytics at CarboGen Laboratories AG, Aarau, Switzerland.
He received his Ph.D. (summa cum laude) from the University of Tuebingen, Germany.
Dr. Rentel has 20 years of experience in Quality Control and analytical method development and validation. He is an expert in mass spectrometric techniques, and has extensive expertise in the development of oligonucleotide therapeutics in regards to specifications, testing of starting materials, reagents, drug substance intermediates, drug substances, drug products and toxicological samples, as well as installation and validation of IT Quality Systems. He has been responsible for the CMC drug substance section of IND filings for more than 40 oligonucleotides, and participated in the NDA filings for mipomersen, nusinersen, volanesorsen and inotersen.